Oncternal Therapeutics (ONCT) - Quarterly EPS earnings growth

Official company branding of Oncternal Therapeutics, Inc. (ONCT)

Oncternal Therapeutics management is implementing advanced methods to combat resistant tumors, establishing new standards of care. The quarterly EPS change reflects the dynamics of this strategy, where the 14.30 level serves as a critical benchmark. Oncternal Therapeutics is developing robust R&D capabilities in molecular synthesis and targeted inhibitors. The business is currently focusing on clinical trials of ROR1 inhibitors for the therapy of lymphomas.

Oncternal Therapeutics, Inc. (ONCT) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 12/14/2024

Analytical breakdowns for Oncternal Therapeutics

- market value and analyst target forecast:
Fundamental company analysis:oncternal.com, ONCT
Manufactured product of Oncternal Corp

Outsourcing the production of targeted lymphoma drugs minimizes capital expenditures for Oncternal Therapeutics (ONCT), directly impacting the bottom line. This trend captures the percentage change in quarterly earnings per share, allowing the quarterly EPS growth profile to reflect the efficiency of the operating model and the fundamental resilience of the business against industry risks.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia (KZIA)|Year-over-year earnings per share growth for the last twelve months silexion.com|NCNA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CMRX|Quarterly EPS earnings growth Cyclacel, Inc. (CYCC)|Year-over-year earnings per share growth for the last twelve months G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Year-over-year net earnings per share trend for the last twelve months|KTRA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc